Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017

Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017

Press Release (ePRNews.com) - NEW DELHI, India - Apr 26, 2017 - DelveInsight’s, “Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017”, the report provides comprehensive insights about microbiome based therapeutic pipeline products. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under this category.

This report provides information on the microbiome based therapeutic development dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products.

Microbiome is the highly growing fields in the biopharmaceutical industry. The therapeutics is used across many therapy areas. Major therapy areas focused by pipeline drugs for microbiome are Central Nervous System, Dermatology, Gastrointestinal, Metabolic Disorders, Infectious Disease, Ophthalmology and Ear Nose Throat Disorders. There are total 70+ drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 10 product are in Phase I, 1 product is in Phase 0. Around 30+ products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products are in the unknown stage of development. Companies have also gone in collaboration with different partners.

Reports Highlights

• Microbiome-based therapeutic pipeline scenario
• Collaborations & partnering deals
• Current Prominent Research Areas and Key Players
• Pipeline product profiles focusing on Microbiome-based Technologies
• Licensing opportunities
• Market Drivers and Barriers

Scope of the report

• Overview of the global Microbiome-based therapeutic pipeline scenario, products, and associated companies information
• Coverage of global Microbiome-based therapeutic products under development
• Competitive landscape of products for key players and related indications
• Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
• Highlights of licensing & collaboration opportunities and funding details
• Highlights of latest Microbiome-based technologies
• Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

For more details, pricing and sample pages please click this link:


About DelveInsight

DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

Contact Information:

DelveInsight Business Research

Contact number: +91-11-4568 9769

email: info@delveinsight.com


Source : DelveInsight Business Research
Business Info :

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.